FDA will consider Moderna's mRNA flu vaccine after all

Share

1

The FDA will review Moderna's mRNA influenza vaccine after a dispute previously blocked its application.
2

Moderna's clinical trial showed the vaccine was more effective in adults aged 50 and older compared to standard flu shots.
3

The FDA's refusal to file letter cited the trial's lack of a comparison with a specific flu shot for those 65 and older.
4

Moderna is seeking full approval for adults 50 to 64 and accelerated approval for those 65 and older.
5

The FDA aims to make a decision on the vaccine application by August 5, with hopes for market availability later this year.